209 related articles for article (PubMed ID: 35703246)
1. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
Agoro R; White KE
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
[TBL] [Abstract][Full Text] [Related]
2. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
4. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.
Czaya B; Faul C
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461904
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
Courbon G; Martinez-Calle M; David V
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
[TBL] [Abstract][Full Text] [Related]
6. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
8. Non-renal-Related Mechanisms of FGF23 Pathophysiology.
Hanudel MR; Laster M; Salusky IB
Curr Osteoporos Rep; 2018 Dec; 16(6):724-729. PubMed ID: 30353318
[TBL] [Abstract][Full Text] [Related]
9. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
10. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
12. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23.
Ikeda Y
Kidney Int; 2021 Jul; 100(1):14-16. PubMed ID: 34154707
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
[TBL] [Abstract][Full Text] [Related]
14. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
[TBL] [Abstract][Full Text] [Related]
15. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia.
Agoro R; Montagna A; Goetz R; Aligbe O; Singh G; Coe LM; Mohammadi M; Rivella S; Sitara D
FASEB J; 2018 Jul; 32(7):3752-3764. PubMed ID: 29481308
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
18. FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia.
Figurek A; Rroji M; Spasovski G
Cells; 2023 Feb; 12(4):. PubMed ID: 36831276
[TBL] [Abstract][Full Text] [Related]
19. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review).
Zhang R; Wang SY; Yang F; Ma S; Lu X; Kan C; Zhang JB
Exp Ther Med; 2021 Oct; 22(4):1159. PubMed ID: 34504604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]